论文部分内容阅读
目的从药物经济学角度对治疗晚期非鳞非小细胞肺癌(NSCLC)3种化疗方案的临床疗效和成本-效果进行评价和分析,为临床合理用药提供参考。方法采用回顾性分析法,将2014年6月至2015年6月在住院的58例采用培美曲塞、吉西他滨和多西他赛联合顺铂化疗的晚期非鳞NSCLC患者,按治疗方法不同随机分为3组,A组培美曲塞+顺铂方案(21例)、B组吉西他滨+顺铂方案(19例)和C组多西他赛+顺铂方案(18例),均在治疗2个周期后评价疗效。运用药物经济学的成本-效果分析法进行研究。结果 A、B、C组的有效率分别为42.9%、36.8%和38.9%(P>0.05)。成本-效果比(C/E)分别为171.5、104.6和66.1,C组显著低于A和B组(P<0.05)。结论多西他赛+顺铂方案是3种化疗方案中最优势的治疗方案。
Objective To evaluate and analyze the clinical efficacy and cost-effectiveness of three chemotherapy regimens in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC) from the perspective of pharmacoeconomics, and provide a reference for clinical rational drug use. Methods A retrospective analysis was performed in 58 patients with advanced non-squamous NSCLC treated with pemetrexed, gemcitabine and docetaxel combined with cisplatin in our hospital from June 2014 to June 2015. All patients were randomized according to different treatment methods Patients in group A received pemetrexed plus cisplatin (n = 21), group B received gemcitabine plus cisplatin (n = 19), and group C received docetaxel plus cisplatin (n = 18) After 2 cycles evaluation of efficacy. Using cost-effectiveness analysis of pharmacoeconomics. Results The effective rates in groups A, B and C were 42.9%, 36.8% and 38.9%, respectively (P> 0.05). The cost-effect ratios (C / E) were 171.5, 104.6 and 66.1, respectively, which were significantly lower in group C than those in group A and B (P <0.05). Conclusion Docetaxel + cisplatin regimen is the most superior of the three chemotherapy regimens.